Tablet explosive growth Ephragm needle sword refers to the PPI market feast

On January 8, Lizhu Group received the CFDA approved the issuance of drug registration approval, approved the injection of sodium eprasium production and marketing, the product named "Lian Lian", dosage form for powder needles, specifications of 10mg. The product lasted 9 years of research and development to the end of the market, the future will become a new performance growth point of Lizhu.
injection of sodium Aprazole is an innovative drug independently developed by Lizhu Group, mainly used to treat peptic ulcer bleeding, with long acid suppression time, small individual differences, less drug interaction and other advantages, once a day. The enterprise already has Aprazo tablets, needles two dosage form exclusive products, competitive advantage is obvious, growth space is huge.
Aprazole belongs to a new generation of proton pump inhibitors, is the only innovative drug in the field of digestion in China, its intestinal solution tablets on December 11, 2007 was approved by the CFDA for the treatment of heterointestinal ulcers. According to the securities company, sales of Eprasium tablets in 2016 were 285 million yuan. After the market of powder needles, considering that the sales of similar pythonazole, lanso lazi, omeprazole and Esomerazole are above the 1 billion yuan level, so the injection of sodium eprazo is also expected to become 1 billion to 2 billion grade products.injections have a wide

peptic ulcers are a common chronic disease of the digestive system, and are easy to treat and prone to recurrent seizures. There are a wide variety of therapeutic drugs, including anti-acid drugs, gastric mucosa protectors, H2 subject blockers, proton pump inhibitors, traditional Chinese medicine and so on. Among them, proton pump inhibitors are currently the strongest anti-acid effect, the best clinical efficacy, the most widely used clinical class of drugs, market share of more than 90%. According to statistics, the overall market sales of proton pump inhibitors in China in 2016 exceeded 7.334 billion yuan, the market is huge. Eprasium was the first proton pump inhibitor developed by China to fill the gap in China.
currently, domestic listed proton pump inhibitors include lutonazole, lanso laazole, omeprazole, Essomerazole, reberazole, and eprazole. According to domestic sample hospital statistics, in 2016, sales of 1.95 billion yuan, Lanso laazole 1.90 billion yuan, Omerazole 1.41 billion yuan, Esso meprazole 993 million yuan, Reberazole 622 million yuan, 152 million yuan. Among them, the top 4 products are sales of 1 billion to 2 billion yuan between large products.tablets explosive growth
Lizhu Group's Eprah intestinal solution was approved by the CFDA in December 2007 listed, the commodity is called "Lian", the specification of 5mg, mainly used for the treatment of diothyl ulcers and stomach ulcers, the drug after oral selective entry into the stomach wall cells, converted into subsulsamide active metabolites, play a therapeutic role.
according to domestic sample hospital statistics, the domestic market has six proton pump inhibitor products, Aprazole intestinal tablets on the market the latest. In 2009, the sales of the sample hospital in Aprasse reached 970,000 yuan, in 2015 sales reached 105 million yuan, in 2016 it was 152 million yuan, and is expected to be 220 million yuan in 2017, an increase of more than 40.0% year-on-year.
in recent years, the market for Aprazole has shown explosive growth and momentum, and has become the fastest growing product in the clinical use of proton pump inhibitors in the last two years.Seven to share the PPI market feast
injectable eprazine was submitted for listing in June 2016, and on October 28, 2016, the product was listed as a priority review drug for innovative drugs with significant clinical value and for significant specific reasons. It took more than a year from entry into priority review to approval of production.
According to sample hospital statistics, in the first three quarters of 2017, proton pump inhibitor injection sales of 3,758 million yuan, oral preparation sales of 1,685 million yuan, injection and oral form sales ratio of about 7:3, domestic sales of injections accounted for a relatively high. Lizhu injection with Aprazole market, it is expected that through the intestinal tablets have been laid down marketing channels and market base to achieve rapid release, sharing the domestic proton pump inhibitor market feast. (Medical Economics)